201 related articles for article (PubMed ID: 30733293)
21. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
Hurvitz SA; Kalous O; Conklin D; Desai AJ; Dering J; Anderson L; O'Brien NA; Kolarova T; Finn RS; Linnartz R; Chen D; Slamon DJ
Breast Cancer Res Treat; 2015 Feb; 149(3):669-80. PubMed ID: 25663547
[TBL] [Abstract][Full Text] [Related]
22. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
23. Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy.
Biri-Kovács B; Adorján A; Szabó I; Szeder B; Bősze S; Mező G
Biomolecules; 2020 Jan; 10(2):. PubMed ID: 31991749
[TBL] [Abstract][Full Text] [Related]
24. Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
Li G; Xie Q; Yang Z; Wang L; Zhang X; Zuo B; Zhang S; Yang A; Jia L
Int J Cancer; 2019 Dec; 145(12):3285-3298. PubMed ID: 31111958
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
26. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
[TBL] [Abstract][Full Text] [Related]
27. Clarifying CB2 receptor-dependent and independent effects of THC on human lung epithelial cells.
Sarafian T; Montes C; Harui A; Beedanagari SR; Kiertscher S; Stripecke R; Hossepian D; Kitchen C; Kern R; Belperio J; Roth MD
Toxicol Appl Pharmacol; 2008 Sep; 231(3):282-90. PubMed ID: 18556036
[TBL] [Abstract][Full Text] [Related]
28. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
29. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
[TBL] [Abstract][Full Text] [Related]
30. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
[TBL] [Abstract][Full Text] [Related]
31. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
32. C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
Li W; Xu L; Che X; Li H; Zhang Y; Song N; Wen T; Hou K; Yang Y; Zhou L; Xin X; Xu L; Zeng X; Shi S; Liu Y; Qu X; Teng Y
BMC Cancer; 2018 May; 18(1):507. PubMed ID: 29720121
[TBL] [Abstract][Full Text] [Related]
33. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
[TBL] [Abstract][Full Text] [Related]
34. Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
Huang Y; Burns DJ; Rich BE; MacNeil IA; Dandapat A; Soltani SM; Myhre S; Sullivan BF; Lange CA; Furcht LT; Laing LG
BMC Cancer; 2017 Mar; 17(1):199. PubMed ID: 28302091
[TBL] [Abstract][Full Text] [Related]
35. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
36. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
37. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
[TBL] [Abstract][Full Text] [Related]
38. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]